Opportunities and Challenges in Development of Live Biotherapeutic Products to Fight Infections

Abstract Treatment of bacterial infections with broad-spectrum antibiotics is a strategy severely limited by the decreased ability of the perturbed resident microbiota to control expansion of antibiotic-resistant pathogens. Live biotherapeutic products (LBPs) could provide an alternative to antibiot...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of infectious diseases 2021-06, Vol.223 (Supplement_3), p.S283-S289
Main Authors: Ducarmon, Quinten R, Kuijper, Ed J, Olle, Bernat
Format: Article
Language:English
Subjects:
Antibiotic resistance
Antibiotics
Colonization
Digestive system
Drug development
Fecal microflora
Intellectual property
Microbiota
Multidrug resistance
Transplantation
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Treatment of bacterial infections with broad-spectrum antibiotics is a strategy severely limited by the decreased ability of the perturbed resident microbiota to control expansion of antibiotic-resistant pathogens. Live biotherapeutic products (LBPs) could provide an alternative to antibiotics in infection control by restoring gut colonization resistance and controlling expansion of resistant strains, an important therapeutic need not being addressed with existing anti-infective drug modalities. We review opportunities and challenges in developing LBPs for multidrug-resistant organisms colonization and infection control, with a focus on commercial fecal microbiota transplantation-like products and defined bacterial consortia, and spanning considerations related to availability of models for rational drug candidate selection and dose regimen selection, good manufacturing practice, intellectual property, and commercial viability.
ISSN:0022-1899
1537-6613
DOI:10.1093/infdis/jiaa779